| All patients | Depression | P value | ||||
---|---|---|---|---|---|---|---|
none | mild | moderate | moderately severe | severe | |||
No. of patients | 267 | 110 | 80 | 43 | 26 | 8 | Â |
Age (year) | 62.9 ± 12 | 62.3 ± 12.7 | 62.2 ± 11.6 | 63.5 ± 12.1 | 64.0 ± 9.7 | 70.1 ± 12.5 | p = 0.3b |
Sex (M:F) | 131:136 | 57:53 | 36:44 | 25:18 | 11:15 | 2:6 | p = 0.5a |
Weight (kg) | 64.9 ± 13.1 | 65.4 ± 13.7 | 63.3 ± 11.6 | 66.2 ± 15.0 | 66.1 ± 12.2 | 61.9 ± 14.3 | p = 0.9b |
Height (cm) | 160.2 ± 7.8 | 161.0 ± 7.8 | 159.0 ± 7.5 | 162.0 ± 7.5 | 159.0 ± 8.9 | 158.0 ± 6.4 | p = 0.4b |
Duration of dialysis (months) | 30.9 (13.8–62.1) | 29.6 (14.9–55.7) | 30.5 `(13.1–62.5) | 42.7 (17.1–70.5) | 22.4 (12.9–59.7) | 38.4 (35.4–49.3) | p = 0.8b |
Renal diagnosis, no. of patient (%) |  |  |  |  |  |  | p = 0.17a |
 diabetic nephropathy | 98 (36.7%) | 37 (33.6%) | 27 (33.8%) | 20 (46.5%) | 9 (34.6%) | 5 (62.5%) |  |
 hypertensive nephrosclerosis | 30 (11.2%) | 11 (10%) | 9 (11.3%) | 6 (14%) | 4 (15.4%) | 0 (0%) |  |
 glomerulonephritis | 84 (31.5%) | 38 (34.5%) | 25 (31.3%) | 10 (23.3%) | 8 (30.8%) | 3 (37.5%) |  |
 polycystic kidney | 8 (3.0%) | 4 (3.6%) | 3 (3.8%) | 1 (2.3%) | 0 (0%) | 0 (0%) |  |
 urological problems | 11 (4.1%) | 9 (8.2%) | 0 (0%) | 1 (2.3%) | 1 (3.8%) | 0 (0%) |  |
 unknown | 30 (11.2%) | 10 (9.1%) | 14 (17.5%) | 4 (9.3%) | 2 (7.7%) | 0 (0%) |  |
 others | 6 (2.2%) | 1 (0.9%) | 2 (2.5%) | 1 (2.3%) | 2 (7.7%) | 0 (0%) |  |
Comorbidity, no. of case (%) | |||||||
 diabetes | 121 (45.3%) | 47 (42.7%) | 34 (42.5%) | 23 (53.5%) | 11 (42.3%) | 6 (75%) | p = 0.3a |
 ischemic heart disease | 29 (10.9%) | 16 (14.5%) | 13 (16.3%) | 6 (14.0%) | 3 (11.5%) | 0 (0%) | p = 0.5a |
 cerebrovascular disease | 47 (17.6%) | 16 (14.5%) | 15 (18.8%) | 11 (25.6%) | 3 (11.5%) | 2 (25%) | p = 0.3a |
 peripheral vascular disease | 9 (3.4%) | 4 (3.6%) | 0 (0%) | 1 (2.3%) | 3 (11.5%) | 1 (12.5%) | p = 0.4a |
Charlson Comorbidity Index | 5.66 ± 2.51) | 5.45 ± 2.26 | 5.25 ± 2.32 | 5.37 ± 2.12 | 4.81 ± 1.72 | 6.50 ± 2.56 | p = 0.4b |
PD exchange by assistants, no. of case (%) | 34 (12.7%) | 10 (9.1%) | 9 (11.3%) | 8 (18.6%) | 2 (7.7%) | 5 (37.5%) | p = 0.14a |
Baseline biochemistry | |||||||
 serum albumin (g/L) | 33.7 ± 4.37 | 34.1 ± 4.57 | 34.2 ± 3.92 | 31.8 ± 4.39 | 35.0 ± 3.15 | 28.4 ± 3.69 | p = 0.09b |
 total cholesterol (mmol/l) | 4.91 ± 1.35 | 4.95 ± 1.28 | 4.77 ± 1.34 | 4.86 ± 1.54 | 5.13 ± 1.39 | 5.08 ± 1.44 | p = 0.9b |
 LDL cholesterol (mmol/l) | 2.82 ± 1.13 | 2.82 ± 1.04 | 2.66 ± 1.09 | 2.92 ± 1.29 | 3.06 ± 1.20 | 2.89 ± 1.43 | p = 0.8b |
 HDL cholesterol (mmol/l) | 1.31 ± 0.57 | 1.32 ± 0.46 | 1.28 ± 0.53 | 1.21 ± 0.49 | 1.36 ± 0.48 | 1.87 ± 1.70 | p = 0.5b |
 weekly Kt/V | 1.82 ± 0.48 | 1.89 ± 0.53 | 1.81 ± 0.49 | 1.58 ± 0.36 | 1.86 ± 0.37 | 1.86 ± 0.47 | p = 0.08b |
 residual GFR (ml/min/1.73m2) | 1.46 ± 2.00 | 1.87 ± 2.25 | 1.34 ± 1.73 | 0.85 ± 1.87 | 1.33 ± 1.67 | 0.39 ± 0.81 | p = 0.003b |